secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0000784199-21-000203
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CryoLife Q3 revenue $72.2M (+11% YoY); net income $10.6M; non-GAAP EPS ($0.03)
------------------------------------------------------------------------------

- Revenue $72.2M, up 11% GAAP and 9% constant currency vs Q3 2020.
- GAAP net income $10.6M ($0.26 EPS) vs net loss ($2.9M) year ago.
- Non-GAAP net loss ($1.2M) ($0.03 EPS) vs prior non-GAAP net income $4.9M ($0.13).
- 2021 outlook: full-year revenue $296-299M; Q4 $76.5-79.5M, pro forma constant currency growth 9.5-13.7% vs Q4 2019.
- Submitted PMAs to FDA for PerClot and PROACT Mitral; approvals expected in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419921000203/0000784199-21-000203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419921000203/cry-20211104x8k.htm
  HTML page:      https://secwatch.observer/filing/0000784199-21-000203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer